Ruxolitinib Cream Demonstrates Long-Term Safety and Disease Control in Young Patients With Atopic Dermatitis
RAD 2025: In the TRuE-AD3 study, participants aged 2-6 and 7-11 years spent nearly half of the long-term treatment period free of medication.
Nemolizumab Improves Pruritis, Sleep Within 2 Days When Added to Standard Topical Therapy for Atopic Dermatitis
RAD 2025: Nemolizumab as adjunctive therapy to topical steroids with/without topical calcineurin inhibitors provided rapid relief in moderate-to-severe atopic dermatitis.
Dupilumab Sustains Long-Term Reduction of Staphylococcus aureus in Patients with Atopic Dermatitis
RAD 2025: Researchers observed a marked reduction and low burden of viable S. aureus on lesional and non-lesional skin after 1 year of dupilumab treatment.
The Evolving Perception and Utilization of Antiobesity Drugs: Expert Discussion
Donna Ryan, MD, highlights how the media has helped to reframe obesity as a chronic disease and how antiobesity drugs are transforming metabolic disease treatment.
INTEGUMENT-OLE: Roflumilast Cream Maintains Long-Term Disease Control in Pediatric and Adolescent Atopic Dermatitis
RAD 2025: Roflumilast cream significantly improved atopic dermatitis in children and adolescents through 52 weeks, offering a safe, effective treatment option.
Lebrikizumab Maintains Deep Response, QoL Through 3 Years in Atopic Dermatitis Extension Study
RAD 2025: Under lebrikizumab maintenance treatment in week 16 responders, approximately 8 out of 10 achieved almost clear skin up to 3 years.
Real-World Abrocitinib Study Shows Most Patients Maintain Consistent Dosing in Atopic Dermatitis Treatment
RAD 2025: This unique study design simulates the real-world use of JAK inhibitors in tailored treatment regimens with flexibility to manage AEs.
Patient Survey Highlights Importance of Itch Relief, Personalized Guidance in Atopic Dermatitis Treatment
RAD 2025: More than 80% of people would want, or would consider, a test that would direct them towards a more effective therapy for their AD, according to new data.
Women’s Health Takeaways for Primary Care: Expert Insights From ACOG 2025
Hear experts' takeaways from ACOG 2025 on menopause care, postpartum depression screening, and obesity management.
From HPV to GLP-1 RA: Primary Care Quiz on Recent Women’s Health & Endocrine Evidence
From HPV vaccination to PCOS management, this quiz is designed for primary care providers who want to stay ahead in women's health.
Older Adults are Open to Cognitive Assessment for Dementia in Primary Care But Obstacles Loom Large, a New Study Finds
A study reveals low clinician engagement in digital cognitive assessments for dementia in primary care, highlighting workflow and other barriers to early detection.
Future of Obesity Care: 3 Wishes from Thought Leader Donna Ryan, MD
When asked about her 3 wishes for the future of obesity care, Donna Ryan, MD, told Patient Care that she had just one: access.
Social Determinants of Health Affect Use of HRT During Menopause, Study Suggests
Social determinants including partner status, smoking history, and BMI were significantly associated with reduced access to effective hormone therapy for menopausal women.
Guardant Health's Shield Mutlicancer Detection Blood Test Granted FDA Breakthrough Device Designation
Breakthrough device designation for the multicancer detection test is supported by clinical validation data demonstrating an overall specificity of 98.6% and sensitivity of 60%.
Postpartum Hormonal Contraceptives Up Depression Risk by 50%: Daily Dose
Your daily dose of the clinical news you may have missed.
CDC: Measles Vaccine Strongly Recommended for All International Travelers
The CDC recommendation pertains to all international travel, regardless of destination, as a result of rising case numbers in the US.
Bringing PPD Screening to the Forefront of Maternal Health: A Q&A with Joy Baker, MD
ACOG 2025: Joy Baker, MD, discusses the urgent need to prioritize postpartum depression screening, normalize mental health in prenatal care, and strengthen continuity between OB-GYN and primary care.
ctDNA Blood Test Showed High Sensitivity, Specificity for Colorectal Cancer but Poor Sensitivity for Advanced Precancerous Neoplasia
A new study of a circulating tumor DNA-based screening test revealed promising sensitivity and specificity for for CRC, but only 12.5% sensitivity for advanced neoplasia.
OASIS-4 Trial: Elinzanetant Reduces Frequency of Vasomotor Symptoms Related to Endocrine Therapy for HR-Positive Breast Cancer
ASCO 2025. Elinzanetant significantly reduced the frequency of VMS vs placebo in women on endocrine therapy for treatment or prevention of HR+ breast cancer.
Phase 2 Dose-Finding Study of Intranasal Epinephrine Powder (NS002) Supports Development for Regulatory Submission
Nasus Pharma says promising phase 2 results for FMXIN002 show statistically significantly faster absorption than traditional autoinjectors and are published in global journal.
